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Clinical Laboratory Assessment of Mycoplasma genitalium
Transcription-Mediated Amplification Using Primary Female
Urogenital Specimens
Erik Munson,a,b Holly Bykowski,a Kimber L. Munson,a Maureen Napierala,a Pamela J. Reiss,a Ronald F. Schell,c,d,e Jeanne E. Hryciuka
Wheaton Franciscan Laboratory, Milwaukee, Wisconsin, USAa; College of Health Sciences, Marquette University, Milwaukee, Wisconsin, USAb; Wisconsin State Laboratory
of Hygiene, Madison, Wisconsin, USAc; Departments of Microbiologyd and Medical Microbiology and Immunology,e University of Wisconsin—Madison, Madison,
Wisconsin, USA
Following analysis of primary cervix, vagina, and first-void female urine specimens for Chlamydia trachomatis, Neisseria gonor-
rhoeae, and Trichomonas vaginalis via commercial transcription-mediated amplification (TMA), residual material was subjected
toMycoplasma genitalium research-use-only TMA. Representation within a 2,478-specimen retrospective study set was estab-
lished by comparison to a 6-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of the C. trachomatis
detection rate, specimen source distribution, clinic location, and age.M. genitaliumwas detected in 282 (11.4%) patients. This
rate was higher than those seen with T. vaginalis (9.0%; P 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%). Positive
M. genitalium results were confirmed by repeat testing or alternative-target TMA at a rate of 98.7%. The mean age of theM.
genitalium-infected females (24.7 years) was lower than that of the T. vaginalis-infected females (mean, 30.1 years; P< 0.0001)
and higher than that of the C. trachomatis-infected females (mean, 23.8 years; P 0.003). Of 566 patient encounters positive for
at least one sexually transmitted infection (STI), 35.9% exhibited sole detection of M. genitalium (P< 0.0004 versus sole de-
tection of other STI agents) and 26.1% were solely positive for T. vaginalis (P< 0.0002 versus C. trachomatis). TheM. genita-
lium and T. vaginalis detection rates among 755 patients at urban emergency departments were 14.6% and 13.0%, respectively
(P 0.37). A 10.0%M. genitalium detection rate from other facilities exceeded that of T. vaginalis (7.2%; P 0.004). Incorpora-
tion ofM. genitalium TMA into comprehensive testing programs would detectM. genitalium in a significant proportion of fe-
males, particularly those in outpatient obstetrics and gynecology (OB/GYN) settings.
The sexually transmitted infection (STI) agent Mycoplasmagenitalium has historically had a role of pathogenicity in male
nongonococcal urethritis (1). Recent evidence has implicated the
bacterium in clinically significant disease in females (2, 3). Addi-
tional studies suggest thatM. genitalium infection promotes HIV
acquisition (4–6) and virus shedding (7, 8). Moreover, in a recent
meta-analysis, Lis et al. (9) reported significant associations be-
tweenM. genitalium infection and cervicitis, pelvic inflammatory
disease, preterm birth, and spontaneous abortion.
Until recently, a lack of reliable testing options has curtailed
laboratory diagnosis ofM. genitalium infection. Culture and sero-
logic modalities have been limited by sensitivity and/or cross-re-
activity with othermycoplasmas (1) and are becoming supplanted
by molecular diagnostics, largely on a research basis. PCR-based
assays have correlated M. genitalium DNA burden with clinical
condition (10, 11) and treatment efficacy (12) in males. Quanti-
tative molecular analysis has sought to study progression of geni-
tal disease in females (13). In the realm of laboratory diagnosis,
initial studies of target capture-based transcription-mediated
amplification (TMA) in females reported 87.8% (14) and
96.9% (15) sensitivity values from vaginal specimens. PCR sen-
sitivity values from the same cohorts were 92.9% and 93.8%,
respectively.
We recently demonstrated the utility of TMA-basedM. genita-
lium detection in male specimens originating from both STI and
community outpatient clinics (16). In contrast, previous studies
ofM. genitaliumTMA in females have largely focused on high-risk
demographics (14, 15, 17–19). Assessment ofM. genitalium detec-
tion rates in a communitywide setting would be beneficial. We
now provide findings of the importance of TMA-basedM. genita-
lium evaluation of females in a metropolitan health care system.
(Results of this work were previously presented, in part, at the
115th GeneralMeeting of the American Society forMicrobiology,
New Orleans, LA, 30 May to 2 June 2015.)
MATERIALS AND METHODS
Setting. In addition to seven acute care facilities, Wheaton Franciscan
Laboratory serves an approximately 125-clinic metropolitan outpatient
physician group in a three-county region of southeastern Wisconsin. A
portion of this service area extends beyond the Milwaukee-Waukesha-
West Allis metropolitan statistical area (MSA). Analyses of data fromU.S.
MSAs document a long-standing trend of high STI prevalence in theMil-
waukee-Waukesha-West AllisMSA. Aggregation of these data revealed an
average chlamydia rate of 678.0 per 100,000 population over a 10-year
interval (20). This value averaged the second highest in the United States
and represented a 77.3% increase over the average national cumulative
MSA rate of 382.3 per 100,000 population. The same MSA generated an
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average annual rank of 2.56 for gonorrhea rate amongUnited StatesMSAs
(264.0 per 100,000 population; 112.6% higher than the nationalMSA rate
of 124.2 per 100,000 population).
Specimen submission for routine screening. Approximately 2-ml
aliquots of first-void female urine were added to Aptima urine specimen
transport tubes per the Aptima Combo 2 Assay (Hologic, Incorporated,
San Diego, CA) package insert protocol following specimen procurement
(21). Aliquots were stored at 2 to 30°C and tested within 30 days of pri-
mary collection. Primary genital swab specimens were obtained using an
Aptima unisex swab specimen collection kit (21), stored at 2 to 30°C, and
tested within 30 days of collection.
The Aptima Combo 2 Assay was utilized for the detection of N. gon-
orrhoeae-specific 16S rRNA and Chlamydia trachomatis-specific 23S
rRNA (22) from all urine aliquots. The samples were additionally sub-
jected to Aptima Trichomonas vaginalis (Hologic) testing for detection of
organism-specific 18S rRNA (23).
Retrospective specimen collection forM. genitalium TMA analysis.
A 6-month laboratory information system-based audit of female STI or-
dering practices was conducted for the purpose of assembling a represen-
tative study set for M. genitalium TMA. Assessed parameters included
specimen source (urine, cervical specimen, or vaginal specimen), C. tra-
chomatis detection rate, geographic location, and patient age. This study
was governed by theWheaton FranciscanHealthcare Institutional Review
Board.
Molecular detection ofM. genitalium. Residual clinical material was
subjected to a research-use-only TMA-based assay for detection of M.
genitalium-specific 16S rRNA (referred to as M. genitalium TMA; Ho-
logic). Reagents were prepared by using Aptima general-purpose reagents
spiked with M. genitalium-specific oligonucleotides. A 50-l aliquot of
target capture oligonucleotide was spiked into Aptima target capture re-
agent; 50-l aliquots of T7 and non-T7 oligonucleotides were spiked into
reconstituted Aptima reconstitution reagent; and a 50-l aliquot of acri-
dinium ester-labeled hybridization oligonucleotide was spiked into Ap-
tima hybridization buffer. All assays were performed on an automated
TIGRIS DTS platform (Hologic).
Interpretation of results. M. genitalium TMA relative-light-unit val-
ues of50,000 derived fromurogenital specimen testingwere interpreted
as representing positive results (14, 17). A subset of positive results, as
each residual specimen allowed, was confirmed by repeat testing. An ad-
ditional subset of positive specimens was forwarded for a TMA-based
alternative-target confirmatory assay (Hologic).
Statistical analysis. The STI phenotype was defined as a M. genita-
lium,C. trachomatis,N. gonorrhoeae, andT. vaginalis distributionwithin a
given health care encounter that yielded detection of at least one STI
agent. The significance test of proportions determined if differences in
either the rates of positive screening results or the STI phenotypes were
significant. The t test for independent samples determined if differences in
mean patient age associated with positive results were significant in the
comparisons between STI etiologies. The alpha level was set at 0.05 before
the investigations commenced, and all P values are two tailed.
RESULTS
Collection of specimens for M. genitalium TMA assessment.
Retrospectively collected specimens (n  2,478) were compared
to data gathered from a 6-month audit of routine screening prac-
tices for C. trachomatis. Proportional specimen source distribu-
tions did not differ between routine C. trachomatis screening
practices and specimens gathered for M. genitalium TMA (P 
0.10; Table 1). In addition, C. trachomatis detection rates showed
no difference from those seen in the collection for M. genitalium
TMA (P  0.91). Detection rates stratified by specimen source
were also similar (P 0.85; Table 1). Among the urogenital spec-
imens submitted for routine C. trachomatis screening, 18.6% and
48.0% were derived from females aged 20 and 21 to 30 years,
respectively. Analogous proportions collected for M. genitalium
TMAwere 19.0% and 47.0% (P 0.60 and 0.38, respectively; data
not illustrated). Comparative data for successive age in decades
exhibited no differences (P 0.07).
Twenty health care locations accounted for 89.2% of all rou-
tine C. trachomatis submissions (Table 2). No differences in pro-
portional specimen distributions between routine laboratory C.
trachomatis screening and theM. genitalium TMA collection (P
0.11) or stratified by individual health care location (P  0.28)
were noted. These entities were also the basis for arbitrary cat-
egorization of health care locations as outpatient obstetrics and
gynecology (OB/GYN), inpatient OB/GYN, suburban family
care, urban family care, and emergency room (ER)/urgent care.
Moreover, 242 (9.8%) specimens in the M. genitalium TMA
collection originated from34 additional health care locations (Ta-
ble 2).
Detection ofM. genitaliumRNA.The overall detection rate of
M. genitalium (11.4%) exceeded those of the other STI agents (P
0.005). T. vaginalis also demonstrated increased detection (9.0%
rate) versus C. trachomatis and N. gonorrhoeae (P 0.0003). De-
tection rates forC. trachomatis andN. gonorrhoeaewere 6.2% and
1.4%, respectively. A total of 208 specimens with detectable M.
genitalium contained enough residual material to allow for repeat
analysis; 207 (99.5%) yielded a positive result. In addition, a subset
of 242 specimens was subjected to alternative-target TMA analysis
(Table 3). A 98.8% concordance of results was observed.
Female urogenital specimens with detectableM. genitalium
RNA. The rates of detection ofM. genitalium from 1,896 cervical,
444 urine, and 138 vaginal specimens were 11.5%, 10.1%, and
13.8%, respectively (P  0.23; Fig. 1). In similar fashion, the C.
trachomatis andN. gonorrhoeae detection rates, stratified by spec-
imen source, revealed no differences (P  0.85 and 0.18, respec-
TABLE 1 Distribution of specimen source submissions and C. trachomatis detection rates during a 6-month audit of routine C. trachomatis
screening, with comparison to representative distributions of specimens collected for retrospectiveM. genitalium TMA analysis
Specimen
source
% source distribution within specimens analyzed
in:
P value
% C. trachomatis detection from specimens
analyzed in:
P value
C. trachomatis routine
screening
M. genitalium TMA
assessment
C. trachomatis routine
screening
M. genitalium TMA
assessment
Cervix 77.7 76.5 0.20 6.2 6.2 0.99
Urine 17.5 17.9 0.65 6.3 6.1 0.85
Vagina 4.8 5.6 0.10 6.9 6.5 0.87
Total 6.3 6.2 0.91
Mycoplasma genitalium Detection in Females
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tively). The T. vaginalis detection rate from urine (11.3%) ex-
ceeded the rate from cervical specimens (8.2%; P  0.04) and
was similar to the detection rate (11.6%) from vaginal speci-
mens (P  0.91).
The detection rate ofM. genitalium in females aged20 years
was 16.8%. This rate decreased for each successive age decade (Fig.
2), leading to a 4.6% value in a subset of 22 females aged 60
years.M. genitaliumwas detected in females 14 years to 65 years of
age, with amean age of 24.7 years (data not illustrated). Thismean
was similar to the mean age of N. gonorrhoeae detection (23.5
years; P 0.30) but different from those for C. trachomatis detec-
tion (22.8 years; P 0.003) and T. vaginalis detection (30.1 years;
P 0.0001).
M. genitalium detection delineated by health care setting.
Other than a 9.0% rate of C. trachomatis detection from the ER/
urgent care setting, C. trachomatis and N. gonorrhoeae detection
rates did not exceed 5.4% for a given health care setting (data not
illustrated). Two health care locations, ER/urgent care and outpa-
tient OB/GYN, accounted for 72.1% of specimens analyzed byM.
genitaliumTMA. Specimens fromoutpatient OB/GYNweremore
likely to contain detectable M. genitalium than T. vaginalis (P 
0.001; Table 4). In contrast, specimens from ER/urgent care had
similarly high rates of M. genitalium and T. vaginalis detection
(14.6% and 13.0%, respectively; P 0.37).
Codetection of other STI agents withM. genitalium.M. geni-
talium was a component of 49.8% of the female STI phenotypes
and the sole component of 35.9% of the phenotypes in this study
(Table 5). Sole detection of T. vaginalis was observed with 26.1%
of the phenotypes; T. vaginalis was a constituent of 39.2% of the
STI phenotypes (P  0.0004 compared to M. genitalium). These
values were greater than the analogous data forC. trachomatis and
N. gonorrhoeae.
In general, equal abundances ofM. genitalium- and T. vagina-
lis-based STI phenotypes existed among the inpatient OB/GYN,
family care, and ER/urgent care settings (P 0.26; Table 5). How-
ever, 41.3% of the outpatient OB/GYN phenotypes consisted of
sole M. genitalium detection, while sole detection of T. vaginalis
comprised 21.8% of the phenotypes (P 0.0002).
Of the 282 specimens with detectable M. genitalium, only
28.0% revealed detection of an additional STI agent (data not
illustrated). Between 28.6% and 36.6% of inpatient OB/GYN,
family care, and ER/urgent care specimens with detectable M.
genitalium involved codetection with another STI agent. In con-
trast, only 19.8% of the outpatient OB/GYN specimens testing
positive forM. genitalium exhibited an additional STI agent.
DISCUSSION
Evidence for the clinical significance of M. genitalium in female
reproductive tract disease is increasing. Lis et al. (9) demonstrated
a significant association ofM. genitalium incidence and increased
risk of cervicitis with a pooled odds ratio (OR) of 1.65. A pooled
OR of 2.53 (adjusted for coinfection) was calculated for an asso-
ciation with pelvic inflammatory disease. When studies utilizing
serodiagnosis were excluded, theOR increased to 2.73. Additional
meta-analyses associated M. genitalium infection with increased
risk of preterm birth (pooled OR of 2.33, accounting for coinfec-
tion) and spontaneous abortion (pooled OR of 1.82). These data
point out a clinical need for effective laboratory diagnostics spe-
cific to this STI agent.
Our data show elevated rates of M. genitalium detection in
females, with significantly greater rates than those for Trichomo-
nas vaginalis—a pathogen previously demonstrated to be present
in abundance in the high-prevalence Milwaukee STI community
(24, 25). Of 282 detections ofM. genitalium, 237 were subjected to
confirmation by repeat testing or alternative-target TMA; 98.7%
of such tests yielded a positive result. Previous literature has es-
poused the value of repeat testing in the confirmation of positive
TMA results (26). Furthermore, in the course of determining the
specificity of M. genitalium TMA, 213 TMA-negative specimens
were subjected to alternative-target TMA. Only one specimen
(0.5%) yielded a positive result by alternative-target TMA. This
rate of discordant results was less than the 1.6% to 4.6% values
reported forT. vaginalis alternative-target testing (24, 27, 28). The
parasitic species Trichomonas tenax has substantial genetic ho-
mologywithT. vaginalis (29), which hypothetically could contrib-
ute to decreased specificity of T. vaginalis alternative-target TMA,
TABLE 2 Distribution of specimen submissions among the 20 most
frequently visited health care locations during a 6-month audit of
routine C. trachomatis screening and comparison to representative
distributions of specimens collected for retrospectiveM. genitalium
TMA analysis
Health care location
% total specimen
submissions for
C. trachomatis
screeninga
% total specimen
collections forM.
genitalium TMA
assessmentb P value
Outpatient OB/GYN 1 16.69 16.38 0.71
Outpatient OB/GYN 2 9.12 9.60 0.44
Outpatient OB/GYN 3 4.14 4.08 0.89
Outpatient OB/GYN 4 3.21 3.39 0.64
Outpatient OB/GYN 5 3.02 3.39 0.33
Outpatient OB/GYN 6 1.96 1.86 0.73
Outpatient OB/GYN 7 1.54 1.45 0.75
Outpatient OB/GYN 8 1.52 1.49 0.91
Inpatient OB/GYN 1.46 1.69 0.38
Suburban family care 1 3.62 3.55 0.86
Suburban family care 2 1.58 1.53 0.87
Urban family care 1 5.36 5.37 0.99
Urban family care 2 3.21 3.55 0.38
Urban family care 3 2.93 2.70 0.54
ER/urgent care 1 11.95 12.47 0.46
ER/urgent care 2 4.85 4.96 0.80
ER/urgent care 3 5.12 5.00 0.82
ER/urgent care 4 4.06 3.79 0.53
ER/urgent care 5 2.66 2.54 0.73
ER/urgent care 6 1.15 1.41 0.28
Top 20 locations 89.2 90.2 0.11
34 other health care
locations
10.8 9.8 0.11
a Total submissions, 12,999.
b Total collections, 2,478.
TABLE 3 Tandem performance of M. genitalium TMA and alternative-
target TMA assays on a subset of 242 primary female urogenital
specimens
Alternative-target TMA
result
No. ofM. genitalium TMA results
Positive Negative
Positive 27 1
Negative 2 212
Munson et al.
434 jcm.asm.org February 2016 Volume 54 Number 2Journal of Clinical Microbiology
 o
n
 July 12, 2016 by M
arquette University Libraries
http://jcm.asm.org/
D
ow
nloaded from
 
particularly in cases of pharyngeal T. vaginalis carriage (28). The
high specificity for M. genitalium alternative-target TMA implies
lack of cross-reactivity with other mycoplasmas and clearly veri-
fies the increasedM. genitalium detection in this population.
Previous studies ofM. genitaliumTMAhave focused largely on
high-risk demographics. Huppert et al. (17) reported a 22.4% de-
tection rate from 331 female attendees of an adolescent health
center/emergency department. Furthermore, Gaydos et al. (18)
documented an approximate 19% detection rate among female
STI clinic patients. Amajor strength of our large-scale study is the
extrapolation ofM. genitaliumTMA toprimary clinical practice in
a broad geographic area. Data from Tables 1 and 2 confirm the
representative nature of the study set. Past reports from our labo-
ratory have summarized diagnostic assay performance within
high-prevalence STI cohorts (16, 20). Subsequent to these reports,
our laboratory has extended its testing scope to locales outside the
Milwaukee-Waukesha-West Allis MSA.While this has resulted in
decreases of STI etiology detection by the laboratory (e.g., the C.
trachomatis detection rate at [non-MSA] ER/urgent care 3 was
8.9%, while the analogous detection rate at [MSA] ER/urgent care
1 was 13.3%; data not illustrated), it has also provided a diverse
population basis for practical assessment of commercial M. geni-
talium TMA.
Past surveillance efforts in general European and U.S. female
populations using molecular diagnostics (30, 31) have reported
M. genitalium detection rates of 1.0% to 2.3%. A meta-analysis
published byMcGowin and Anderson-Smits (32) calculated a de-
tection rate of 2.0% from low-risk female populations. In a South
American OB/GYN cohort of 1,338 women, Hitti et al. (33) doc-
umented a 3.1% cervical M. genitalium detection rate by TMA.
This report is interesting for a number of reasons. First, it docu-
ments M. genitalium detection in an OB/GYN population and
associates its presence with preterm birth and younger maternal
age. It also reveals a strong association with C. trachomatis detec-
tion and a marginal association with T. vaginalis detection. It
should be noted that those authors utilized culture for laboratory
FIG 1 Cervical, first-void urine, and vaginal specimen detection rates forM. genitalium (solid bars), C. trachomatis (horizontally hatched bars),N. gonorrhoeae
(gray bars), and T. vaginalis (diagonally hatched bars) from 2,478 female patients.
FIG 2 M. genitalium (solid bars), C. trachomatis (horizontally hatched bars), N. gonorrhoeae (gray bars), and T. vaginalis (diagonally hatched bars) detection
rates, delineated by age, from 2,478 female urogenital specimens.
Mycoplasma genitalium Detection in Females
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diagnosis of trichomoniasis, a modality shown to be far less sen-
sitive than molecular diagnostics (34). Our outpatient OB/GYN
population was characterized by an increased rate of M. genita-
lium in general and by a significantly increased rate of M. genita-
lium detection in comparison toT. vaginalis detection (P 0.001;
Table 4).
STI phenotyping essentially predicts the likelihood of a given
etiology for STI diagnosis during a health care encounter. In con-
trast to past reports showing a strong association betweenM. geni-
talium detection and the concomitant presence of C. trachomatis
(17, 33), only 4.2% of total STI phenotypes in our study involved
codetection ofM. genitalium andC. trachomatis (Table 5). Among
the STI phenotypes, 7.1% consisted ofM. genitalium and T. vagi-
nalis codetection. Moreover, while M. genitalium was a constitu-
ent of nearly half of the STI phenotypes, 39.2% and 27.2% of all
phenotypes had some component ofT. vaginalis andC. trachoma-
tis, respectively. Detection rate and STI phenotype data reveal sig-
nificant differences with respect toM. genitalium and T. vaginalis
in the outpatient OB/GYN setting. These clinics were more likely
to produce a significant increase inM. genitalium detection (Table
4) as well as STI phenotypes specific to the organism (Table 5).
The other four arbitrary health care classifications did not experi-
ence this phenomenon. Napierala et al. (16) previously described
a M. genitalium/T. vaginalis dichotomy within a 2,750-male co-
hort in which the STI phenotypes of STI clinic attendees and pa-
tients seeking outpatient clinic care consisted predominately ofM.
genitalium and T. vaginalis, respectively. The differential distribu-
tion of these two STI agents, which apparently may exist to a
degree in both genders, warrants further investigation.
With respect to an optimal specimen source for TMA-based
detection of M. genitalium on a single-specimen basis, Wrob-
lewski et al. (14) discussed the relative sensitivities of vaginal and
cervical specimens, which were 84% and 60%, respectively. The
relative sensitivity of first-void urine specimens was 58% and was
thought to be the result of increased susceptibility of a cell wall-
devoid microbe to lysis in urine. Using an infected-patient stan-
dard, Mobley et al. (19) reported TMA-based M. genitalium sen-
sitivities of 72.6% and 58.9% from vaginal and cervical specimens,
respectively. Our data reveal equivalent M. genitalium detection
rates from cervical specimens (11.5%), vaginal specimens
(13.8%), and first-void urine (10.1%; P  0.23). However, our
data are limited by the fact that not all three specimen sourceswere
submitted from a given patient during routine clinical practice.
Therefore, comparison of performance characteristics by speci-
men source could not be accomplished in this retrospective assess-
ment. Of further interest, previous studies in our female patient
population demonstrated increased T. vaginalis detection from
first-void urine specimens (25, 35). We also show increased T.
vaginalis detection from first-void urine compared to cervical
specimens (P 0.04; Fig. 1). These data trended higher than the
combined cervical specimen/vaginal specimen data (P  0.06).
Some concern lies in how the increased utility of the first-void
urine specimen for T. vaginalis could coexist with the aforemen-
tioned M. genitalium data in the context of (single) specimen
source recommendations for a four-agent STI screen. Additional
large-scale communitywide studies may be necessary to deter-
mine the true utility of urine forM. genitalium TMA, particularly
when such specimens would be assayed for the organism in rou-
tine fashion without prolonged specimen storage.
In summary, increased detection rates of M. genitalium in a
communitywide setting over those of other STI agents, including
T. vaginalis, suggest thatM. genitaliumTMA can provide a benefit
to multiple demographics and multiple clinical practice special-
ties. In addition, the setting of the outpatient OB/GYN is itself an
important area for M. genitalium screening. M. genitalium TMA
has recently become commercially available in an analyte-specific
reagent (ASR) format. Prior to FDA clearance in 2011,T. vaginalis
TMA was also commercially available as an ASR. Napierala et al.
(35) demonstrated progressively increased utilization of that assay
over a 3-year interval. Should an analogous pattern be observed
TABLE 4 M. genitalium and T. vaginalis detection rates for females
seeking health care in ER/urgent care and non-ER/urgent care settings
Health care setting n
No. (%) of specimens with
detection of:
P valueM. genitalium T. vaginalis
Outpatient OB/GYN 1,032 106 (10.3) 66 (6.4) 0.001
Inpatient OB/GYN 46 7 (15.2) 5 (10.9) 0.54
Suburban family care 261 18 (6.9) 14 (5.4) 0.47
Urban family care 384 41 (10.7) 39 (10.2) 0.81
ER/urgent care 755 110 (14.6) 98 (13.0) 0.37
TABLE 5 Sexually transmitted infection phenotypes determined by TMA-based assays specific for M. genitalium, C. trachomatis, N. gonorrhoeae,
and T. vaginalis, delineated by category of health care setting
STI phenotypea,b No. (%) of specimens with indicated phenotype(s)b
M. genitalium C. trachomatis N. gonorrhoeae T. vaginalis
Outpatient
OB/GYN
Inpatient
OB/GYN
Suburban
family care
Urban
family care
ER/urgent
care Totalc
    85 (41.3) 5 (41.7) 12 (29.3) 26 (33.8) 75 (32.6) 203 (35.9)
    3 (1.5) 2 (16.7) 3 (7.3) 2 (2.6) 14 (6.1) 24 (4.2)
    14 (6.8) 0 (0.0) 1 (2.4) 11 (14.3) 14 (6.1) 40 (7.1)
    43 (20.9) 0 (0.0) 8 (19.5) 9 (11.7) 30 (13.0) 90 (15.9)
    1 (0.5) 0 (0.0) 1 (2.4) 0 (0.0) 4 (1.7) 6 (1.1)
    7 (3.4) 0 (0.0) 0 (0.0) 2 (2.6) 14 (6.1) 23 (4.1)
    4 (1.9) 0 (0.0) 1 (2.4) 0 (0.0) 8 (3.5) 13 (2.3)
    45 (21.8) 5 (41.7) 13 (31.7) 25 (32.5) 60 (26.1) 148 (26.1)
a, positive nucleic acid amplification test result;, negative nucleic acid amplification test result; STI, sexually transmitted infection.
b Phenotypes that were observed in1.5% of patients from at least two health care settings are included. No significant difference was noted within the excluded comparisons.
c Phenotypes that were observed in1.0% of encounters are not included in this category.M. genitalium was a constituent of 49.8% of all phenotypes, C. trachomatis of 27.2%, N.
gonorrhoeae of 6.0%, and T. vaginalis of 39.2%.
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withM. genitaliumASR, potential benefits of amore-comprehen-
sive STI screen may be realized in the realm of laboratory diagno-
sis and public health.
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